Geert-Jan Mulder MD
Managing Partner
AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions.
The company's proprietary compound, ilofotase alfa, is being developed as a potential enzyme replacement therapy for adult hypophosphatasia (HPP) patients.
In a Phase 1b clinical proof of concept study in adult HPP patients, ilofotase alfa showed a pronounced effect on all HPP disease-specific biomarkers and normalized alkaline phosphatase activity levels. There were no safety concerns with ilofotase alfa in this study, consistent with previous clinical studies with ilofotase alfa in other indications involving about 1000 patients. These data support its further development as a treatment option for adult HPP patients who are currently underserved.
AM-Pharma has a dedicated team driven to bring treatment options to patients in need, their families and healthcare professionals.
Industry
Biotech
Status
Current
Location
The Netherlands
To date, our lead candidate, ilofotase alfa, has been evaluated in approximately 1,000 patients and has established an impressive clinical record of renal protective effects. Forbion has been a long-term, visionary investor since AM-Pharma transitioned to a clinical-stage company. The team’s scientific, clinical, and commercial expertise was instrumental in the strategic redirection of our development plan for ilofotase alfa, and they continue to show their unwavering commitment to bringing promising therapeutic candidates over the finish line, even for high-risk areas such as critical care. As we are approaching enrollment completion for our Phase 2 trial in cardiac surgery-associated renal damage, the Forbion team remains focused on maximizing value for patients, as well as all other stakeholders, by enabling us to demonstrate the therapeutic impact that ilofotase alfa could bring to this area of high unmet medical need.Juliane Bernholz, Ph.D.
CEO of AM-Pharma
>1000
patients enrolled
Forbion team